M-K. Ang scite author profile

Background: LA-NPC can be subtyped by ascending (A; T3-4N0-1), descending (D; T1-2N2-3) and ascending-descending (AD; T3-4N2-3) at diagnosis, depending on the extent of tumor spread. These phenotypes differ by prognoses, but germline and somatic molecular drivers underpinning their tumorigenesis are unknown. We aimed to validate the A and AD subtypes of LA-NPC and investigate for germline variants that are associated with them.

show abstract

652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)

Toh¹,

Yang²,

Hm³

et al. 2022

Annals of Oncology

View full text Add to dashboard Cite

227MO Characterization of minimal residual disease (MRD) post-radiotherapy (RT) in nasopharyngeal carcinoma (NPC) patients identifies a favorable subgroup with low risk of relapse

Neo

Ong²,

Sim³

et al. 2022

Annals of Oncology

View full text Add to dashboard Cite

192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations

Saw

Tan

et al. 2023

Journal of Thoracic Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

M-K. Ang

Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma

266O Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939

652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)

227MO Characterization of minimal residual disease (MRD) post-radiotherapy (RT) in nasopharyngeal carcinoma (NPC) patients identifies a favorable subgroup with low risk of relapse

192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations

Contact Info

Product

Resources

About